Quincy Bioscience Market Research Report

Company Profile

Background

Quincy Bioscience, established in 2004 and headquartered in Madison, Wisconsin, is a biotechnology company dedicated to the discovery, development, and commercialization of innovative technologies aimed at supporting cognitive function and addressing age-related health challenges. The company's flagship product, Prevagen®, is a dietary supplement designed to improve memory and cognitive performance in aging individuals. Prevagen contains apoaequorin, a protein originally discovered in jellyfish, which Quincy Bioscience has patented for use in various products targeting brain health.

Key Strategic Focus

Quincy Bioscience's strategic focus centers on leveraging its proprietary apoaequorin technology to develop supplements that enhance cognitive function and mitigate memory loss associated with aging. The company emphasizes rigorous scientific research and clinical testing to substantiate the efficacy of its products. Prevagen is available over-the-counter in major retail chains, including Walgreens, CVS, Rite Aid, and Vitamin Shoppe, as well as numerous independent health food stores across the United States.

Financials and Funding

As of December 2025, Quincy Bioscience's annual revenue is estimated to be between $25 million and $50 million. The company has raised a total of $239,000 in funding over three rounds, with the most recent funding round occurring on January 1, 2011. In 2015, CapitalSouth Growth Fund exited its investment in Quincy Bioscience, indicating a successful return on investment.

Pipeline Development

Quincy Bioscience's primary product, Prevagen, has undergone extensive clinical testing to demonstrate its effectiveness in improving cognitive function. The company continues to focus on research and development to expand its product offerings in the cognitive health sector. Specific details regarding additional pipeline candidates and their development stages are not publicly disclosed.

Technological Platform and Innovation

The cornerstone of Quincy Bioscience's technological platform is the application of apoaequorin, a protein derived from jellyfish, which has been patented for use in dietary supplements targeting cognitive health. Apoaequorin has achieved self-affirmed GRAS (Generally Recognized as Safe) status, affirming its safety for use in food products. The company manufactures its products in facilities compliant with Good Manufacturing Practices (GMP), ensuring high-quality standards.

Leadership Team

Mark Underwood: Co-founder and President of Quincy Bioscience, Mark Underwood has been instrumental in the company's growth and development, particularly in the commercialization of Prevagen.

Michael Beaman: Chief Executive Officer of Quincy Bioscience, Michael Beaman has played a key role in overseeing the company's strategic direction and operations.

Tony Cords: Chief Financial Officer, responsible for managing the company's financial operations.

Market and Competitor Analysis

Market Insights and Dynamics

The cognitive health supplement market is experiencing growth due to an aging global population and increasing awareness of age-related cognitive decline. Consumers are seeking products that support memory and cognitive function, creating a competitive landscape for companies like Quincy Bioscience.

Competitor Overview

Quincy Bioscience's primary competitors include:

NOW Foods: A well-established company in the health and wellness sector, offering a wide range of dietary supplements.

Nutraceutical Corporation: A global company specializing in the development, manufacturing, and marketing of branded nutritional supplements.

ERApeutics: A biotechnology company focusing on health care supplies, operating in a similar market segment.

These competitors offer products targeting cognitive health and memory support, contributing to a dynamic and competitive market environment.

Strategic Collaborations and Partnerships

Quincy Bioscience has engaged in strategic collaborations to enhance its market presence and product development. Notably, the company has collaborated with academic institutions for ongoing research and holds several patents related to its products, including a recent patent for a composition combining apoaequorin with vitamin D.

Operational Insights

Quincy Bioscience's operational strategy focuses on maintaining high-quality manufacturing standards, as evidenced by its GMP certification. The company also emphasizes transparency and consumer trust, addressing regulatory challenges related to advertising practices to ensure compliance with industry standards.

Strategic Opportunities and Future Directions

Looking ahead, Quincy Bioscience aims to expand its product portfolio by leveraging its proprietary technology to develop new supplements targeting cognitive health. The company is also exploring opportunities to enhance its market position through strategic partnerships and collaborations, particularly in research and development, to drive innovation and meet the evolving needs of consumers seeking cognitive health solutions.